Luciferase Reporter Cell Line - SIHA

SIHA cells are a human cervical squamous cell carcinoma–derived cell line widely used as an in vitro model for studying cervical cancer biology and HPV-associated tumor progression. These cells exhibit epithelial morphology, strong proliferative capacity, and molecular alterations typical of cervical squamous carcinomas, including dysregulated cell cycle control, enhanced survival signaling, and increased invasive potential. SIHA cells are particularly valuable for investigating the biological consequences of high-risk human papillomavirus (HPV) infection and its downstream oncogenic effects on host cellular pathways. The Luciferase Reporter Cell Line – SIHA is generated through stable integration of a luciferase reporter construct driven by pathway-responsive promoters or transcription factor–specific response elements into the parental SIHA background, enabling sensitive, real-time, and quantitative monitoring of transcriptional and signaling activity while preserving the intrinsic properties of the original cancer cell line.

The Luciferase Reporter Cell Line – SIHA is widely applied in cervical cancer research, HPV-related oncogenesis studies, and anti-tumor drug discovery. It is particularly useful for evaluating key signaling pathways involved in cervical carcinoma progression, including PI3K/AKT/mTOR, MAPK/ERK, NF-κB, Wnt/β-catenin, and JAK/STAT signaling, which contribute to cell proliferation, immune evasion, and malignant transformation. The luciferase reporter system provides a robust and highly sensitive readout for assessing pathway activation or inhibition following treatment with small molecules, biologics, or genetic perturbations. This model is commonly used in high-throughput screening of anti-cervical cancer compounds, as well as in mechanistic studies of HPV-driven tumor biology, apoptosis regulation, and therapeutic resistance. Its stability, reproducibility, and quantitative output make it a valuable platform for both fundamental research and preclinical evaluation of targeted therapies in cervical cancer.